{"title":"Ra223预后因素的多中心、国际回顾性研究。","authors":"Takuya Oishi, Hao-Lun Luo, Yoshiomi Hatayama, Hideo Kawaguchi, Daichi Sasaki, Ryuma Tanaka, Noriaki Ishii, Jotaro Mikami, Teppei Okamoto, Hayato Yamamoto, Masahiko Aoki, Yu-Li Su, Yen-Hao Chen, Yen-Hsiang Chang, Yen-Ta Chen, Hung-Jen Wang, Chikara Ohyama, Shingo Hatakeyama","doi":"10.1038/s41598-025-95844-8","DOIUrl":null,"url":null,"abstract":"<p><p>The risk factors for adium-233 dichloride (Ra223) treatment on prognosis remain unclear. We aimed to validate the risk model for a radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively evaluated 345 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and October 2023 in Japan and Tiwan (R2D2 study). The primary purpose of the study was to validate the risk model for poor overall survival (OS) and Ra223 6-cycle incompletion. The secondary purpose was development of an international risk model. The risk model for poor OS included three factors: poor performance status, Ra223 6-cycle incompletion, and prostate specific antigen > 10 ng/mL. The risk model for Ra223 6-cycle incompletion included two factors: prior mCRPC treatments > 2 and extend of bone metastasis (EOD) 3-4. Of 345, we selected 71 and 274 patients with mCRPC for the development and validation cohorts, respectively. The number of risk factors (0-1 vs. 2-3) was significantly associated with for poor OS after Ra223 and OS after mCRPC diagnosis in the validation cohort. Our observation suggests that those factors may associate with favorable survival in patients treated with Ra223.</p>","PeriodicalId":21811,"journal":{"name":"Scientific Reports","volume":"15 1","pages":"10814"},"PeriodicalIF":3.9000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953448/pdf/","citationCount":"0","resultStr":"{\"title\":\"Multicenter, international, retrospective study of prognostic factors for Ra223.\",\"authors\":\"Takuya Oishi, Hao-Lun Luo, Yoshiomi Hatayama, Hideo Kawaguchi, Daichi Sasaki, Ryuma Tanaka, Noriaki Ishii, Jotaro Mikami, Teppei Okamoto, Hayato Yamamoto, Masahiko Aoki, Yu-Li Su, Yen-Hao Chen, Yen-Hsiang Chang, Yen-Ta Chen, Hung-Jen Wang, Chikara Ohyama, Shingo Hatakeyama\",\"doi\":\"10.1038/s41598-025-95844-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The risk factors for adium-233 dichloride (Ra223) treatment on prognosis remain unclear. We aimed to validate the risk model for a radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively evaluated 345 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and October 2023 in Japan and Tiwan (R2D2 study). The primary purpose of the study was to validate the risk model for poor overall survival (OS) and Ra223 6-cycle incompletion. The secondary purpose was development of an international risk model. The risk model for poor OS included three factors: poor performance status, Ra223 6-cycle incompletion, and prostate specific antigen > 10 ng/mL. The risk model for Ra223 6-cycle incompletion included two factors: prior mCRPC treatments > 2 and extend of bone metastasis (EOD) 3-4. Of 345, we selected 71 and 274 patients with mCRPC for the development and validation cohorts, respectively. The number of risk factors (0-1 vs. 2-3) was significantly associated with for poor OS after Ra223 and OS after mCRPC diagnosis in the validation cohort. Our observation suggests that those factors may associate with favorable survival in patients treated with Ra223.</p>\",\"PeriodicalId\":21811,\"journal\":{\"name\":\"Scientific Reports\",\"volume\":\"15 1\",\"pages\":\"10814\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-03-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953448/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scientific Reports\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1038/s41598-025-95844-8\",\"RegionNum\":2,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientific Reports","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41598-025-95844-8","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
Multicenter, international, retrospective study of prognostic factors for Ra223.
The risk factors for adium-233 dichloride (Ra223) treatment on prognosis remain unclear. We aimed to validate the risk model for a radium-233 dichloride (Ra223) on the prognosis of patients with metastatic castration-resistant prostate cancer (mCRPC). We retrospectively evaluated 345 patients with bone metastases-predominant mCRPC who were treated with Ra223 between August 2016 and October 2023 in Japan and Tiwan (R2D2 study). The primary purpose of the study was to validate the risk model for poor overall survival (OS) and Ra223 6-cycle incompletion. The secondary purpose was development of an international risk model. The risk model for poor OS included three factors: poor performance status, Ra223 6-cycle incompletion, and prostate specific antigen > 10 ng/mL. The risk model for Ra223 6-cycle incompletion included two factors: prior mCRPC treatments > 2 and extend of bone metastasis (EOD) 3-4. Of 345, we selected 71 and 274 patients with mCRPC for the development and validation cohorts, respectively. The number of risk factors (0-1 vs. 2-3) was significantly associated with for poor OS after Ra223 and OS after mCRPC diagnosis in the validation cohort. Our observation suggests that those factors may associate with favorable survival in patients treated with Ra223.
期刊介绍：
We publish original research from all areas of the natural sciences, psychology, medicine and engineering. You can learn more about what we publish by browsing our specific scientific subject areas below or explore Scientific Reports by browsing all articles and collections.
Scientific Reports has a 2-year impact factor: 4.380 (2021), and is the 6th most-cited journal in the world, with more than 540,000 citations in 2020 (Clarivate Analytics, 2021).
•Engineering
Engineering covers all aspects of engineering, technology, and applied science. It plays a crucial role in the development of technologies to address some of the world''s biggest challenges, helping to save lives and improve the way we live.
•Physical sciences
Physical sciences are those academic disciplines that aim to uncover the underlying laws of nature — often written in the language of mathematics. It is a collective term for areas of study including astronomy, chemistry, materials science and physics.
•Earth and environmental sciences
Earth and environmental sciences cover all aspects of Earth and planetary science and broadly encompass solid Earth processes, surface and atmospheric dynamics, Earth system history, climate and climate change, marine and freshwater systems, and ecology. It also considers the interactions between humans and these systems.
•Biological sciences
Biological sciences encompass all the divisions of natural sciences examining various aspects of vital processes. The concept includes anatomy, physiology, cell biology, biochemistry and biophysics, and covers all organisms from microorganisms, animals to plants.
•Health sciences
The health sciences study health, disease and healthcare. This field of study aims to develop knowledge, interventions and technology for use in healthcare to improve the treatment of patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
